ABCB1 and cancer: Notably, Natarajan et al. reported that the first clinically tested PIM inhibitor SGI-1776 [62] increased substrate drug-induced apoptosis in ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells.